SMO and basal cell carcinoma: In some cancers, inhibition of the canonical SMO/Hh pathway has been successful, leading to approval by the Food and Drug Administration (FDA) in 2012 and the European Medicines Agency (EMA) in 2013 of the first SMO inhibitor Vismodegib for the treatment of basal cell carcinoma (BBC), encouraging clinical trials in other cancers.